Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference
Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference
PR Newswire
LEXINGTON, Mass.
,
March 2, 2021
/PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that
James Dentzer
, President and Chief Executive Officer of Curis, will present a company overview at the H.C. Wainwright & Co. Global Life Sciences Conference. A pre-recorded presentation will be available for on-demand viewing beginning at 7:00 am ET on
Tuesday, March 9, 2021
.
A webcast of the presentation will be available under “Events & Presentations” in the Investors section of the Company’s website at
www.curis.com
. A replay of the webcast will be available on the Curis website for approximately 90 days following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin’s lymphoma both as a monotherapy and in combination with BTK inhibitor, ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/
1b
trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis’ website at
www.curis.com
.
View original content to download multimedia:
http://www.prnewswire.com/news-releases/curis-to-present-at-hc-wainwright–co-global-life-sciences-conference-301238362.html
SOURCE Curis, Inc.